R. Goedkoop

A Minimally Invasive Device for the Monitoring of 24-hour Intraocular Pressure Patterns

R. Weinreb, K. Mansouri, R. Goedkoop, 2013 .

A randomized phase II trial of 5-fluorouracil, with or without human interferon-β, for advanced colorectal cancer

R. Goedkoop, J. Lizón, A. Villar-Grimalt, 1999, British Journal of Cancer.

Recombinant soluble p55 TNF receptor induces remission, is non-immunogenic and well tolerated in active Crohn's disease: Results of a randomized pilot trial

P. Rutgeerts, M. Noman, G. Assche, 2001 .

Effect of gemcitabine on renal functions in non-small cell lung cancer (NSCLC)

J. Gietema, R. Goedkoop, H. Groen, 1994 .

The effect of postoperative normovolaemic anaemia and autotransfusion on blood saving after internal mammary artery bypass surgery

R. Goedkoop, E. Berreklouw, P. Everts, 1992, Perfusion.

An autologous epidermal equivalent tissue‐engineered from follicular outer root sheath keratinocytes is as effective as split‐thickness skin autograft in recalcitrant vascular leg ulcers

D. Salomon, M. Meurer, J. Hafner, 2003, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Wound Stimulation by Growth-Arrested Human Keratinocytes and Fibroblasts: HP802-247, a New-Generation Allogeneic Tissue Engineering Product

E. Rolland, J. Daróczy, R. Goedkoop, 2010, Dermatology.

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study

P. Rutgeerts, M. Noman, G. Van Assche, 2003, Alimentary pharmacology & therapeutics.

Quality of athlete screening for high-risk cardiovascular conditions-A systematic review.

A. Wilde, R. Goedkoop, A. Malekzadeh, 2023, Scandinavian journal of medicine & science in sports.

Recombinant human interferon-beta (IFNβ-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC)

H. Steinhart, P. Rutgeerts, S. Nikolaus, 2001 .